You are here

  • Home
  • Archive
  • Volume 30, Issue 7
  • Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors

Article info

Article menu
Download PDFPDF
Original research
Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors

Authors

  1. Correspondence to Dr Rosemary Lord, Medical Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, Bebington CH63 4JY, UK; rosemarylord{at}nhs.net
View Full Text

Citation

Lord R, Rauniyar J, Morris T, et al
Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors
International Journal of Gynecologic Cancer 2020;30:1026-1033.

Publication history

  • Received October 1, 2019
  • Revision received December 23, 2019
  • Accepted January 22, 2020
  • First published April 21, 2020.
Online issue publication 
July 06, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.